FDA Grants Priority Review for Rezafungin to Prevent Invasive Fungal Disease

The U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for rezafungin (REZZAYO) and granted it Priority Review. This sNDA seeks approval for rezafungin for the prophylaxis of invasive fungal disease, a serious condition, particularly in critically ill and immunocompromised patients. Rezafungin is already approved for treating candidemia and invasive candidiasis.